Bipartisan 'STRONGER Patents Act' introduced in USA

21 March 2018
2019_biotech_test_vial_discovery_big

On Tuesday, US Representative Steve Stivers (Republican, Ohio) and Representative Bill Foster (Democrat, Illinois) introduced HR 5340, the Support Technology & Research for Our Nation’s Growth and Economic Resilience (STRONGER) Patent Act, in order to strengthen the USA’s crippled patent system.

The STRONGER Patent Act would reverse that trend by standing up for small businesses that rely on patents by providing court-level standards at the United States Patents and Trademark Office and providing injunctive relief against those who infringe on patents. It also protects small patent owners and start-ups by eliminating harassing, duplicitous patent demand letters, many of which are often sent in bad faith by so-called “trolls.” By defining the process of sending superfluous demand letters as a “Deceptive and Unfair Act or Practice,” the STRONGER Patent Act is equipping the Federal Trade Commission (FTC) with the tools necessary to crack down on these trolls.

Welcomed by biotech trade group

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology